A phase Ib dose escalation study of the safety and tolerability of oglufanide disodium (IM862) in patients with chronic hepatitis C virus (HCV) infection.

Trial Profile

A phase Ib dose escalation study of the safety and tolerability of oglufanide disodium (IM862) in patients with chronic hepatitis C virus (HCV) infection.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Oglufanide; Oglufanide
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Implicit Bioscience
  • Most Recent Events

    • 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry record)
    • 08 May 2009 Planned number of patients (32), actual initiation date (1 Nov 2007) added, official title amended as reported by Australian New Zealand Clinical Trials Registry record.
    • 06 Jan 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top